Interactive model of therapeutic response in panic disorder: Moclobemide, a case in point

Journal of Clinical Psychopharmacology

Volumn 22, Issue 3, 2002, Pages 275-284

  Uhlenhuth, E H ^a   Warner, Teddy D ^a   Matuzas, William ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; MOCLOBEMIDE;

ADULT; AGORAPHOBIA; ARTICLE; AVOIDANCE BEHAVIOR; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEAR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOCLOBEMIDE; PANIC DISORDER; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC;

EID: 0036109030     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200206000-00008     Document Type: Article

References (39)

1. Growing placebo response rate: The problem in recent therapeutic trials?
2. Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? a replication
3. Reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program general effectiveness report
4. Statistical treatment of the law of initial values (LIV) in autonomic research: A review and recommendation
5. Modern psychophysiology and the law of initial value
6. Basimetric approach to psychiatry
7. Drug effects and initial severity of symptomatology
8. Psychiatric reaction patterns to imipramine
9. The revised Anxious Thoughts and Tendencies (AT&T) scale: A general measure of anxiety-prone cognitive style
10. MAOIs in the contemporary treatment of depression
11. Columbia atypical depression: A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo
12. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms
13. Monoamine oxidase inhibitors in anxiety disorders
14. The pharmacology of moclobemide
15. Monoamine oxidase inhibitors: Reversible and irreversible
16. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects
17. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression
18. Reversible and selective inhibitors of monoamine-oxidase-A in mental and other disorders
19. Moclobemide in social phobia: A double-blind, placebo-controlled study
20. New uses for antidepressants: Social phobia
21. Moclobemide in social phobia: A controlled dose-response trial
22. Placebo-controlled trial of moclobemide in social phobia
23. Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine
24. Randomized, placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia
25. The assessment of anxiety by rating
26. A rating scale for depression
27. Comorbidity and the general neurotic syndrome
28. Comorbidity among anxiety disorders: Implications for treatment and DSM-IV
29. Depressive comorbidity of panic, social phobia, and obsessive-compulsive disorders reexamined: Is there a bipolar II connection?
30. Panic disorder in the primary care setting: Comorbidity, disability, service utilization, and treatment
31. Axis I and axis II comorbidity in panic/agoraphobic patients with and without suicidal ideation
32. The classification of phobic disorders
33. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder
34. Plasma levels of antipsychotic drugs and clinical response
35. Plasma alprazolam concentrations: Relation to efficacy and side effects in the treatment of panic disorder